Mirdametinib is an oral MEK1/2 inhibitor approved in February 2025 for the treatment of adults170 and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1)171 who have symptomatic, inoperable plexiform neurofibromas. This evidence concerns the gene MAP2K1 and neurofibromatosis type 1.